Dr Michael O'Donnell, BA, MD, Richard D Williams Professor & Director of Urologic Oncology at the University of Iowa Carver College of Medicine and a member of the Holden Comprehensive Cancer Center. Development and enhancement of bladder immunotherapy has been his research focus for more than 20 years, he has also pioneered the use of combination intravesical chemotherapy in early bladder cancer. Personally directed as PI two large multicenter clinical trials involving over 1700 patients as well as several investigator-initiated trials. Over 80% of his active clinical practice is devoted to bladder cancer where he specialize in patients with early non-muscle invasive bladder cancer (NMIBC) who have failed first line therapy with BCG. Also newly involved as an investigator for industry and cooperative group trials involving immune checkpoint inhibitors for NMIBC. Furthermore, as a bladder cancer immunologist, he has applied expertise to investigating pathways of bladder inflammation and chronic pain in interstitial cystitis by establishing an animal models of the disease and by serving as an NIH funded investigator for several national clinical networks including the ICCTG, ICCRN, MAPP and LURN. Major research interests include the development of recombinant BCG for bladder cancer immunotherapy; deciphering the mechanism of anti-cancer action of BCG and cytokines; and the role of death receptors in mediating cancer apoptosis; biomarkers of successful cancer therapy; Role of Toll Like Receptors in bladder pain and inflammation; and defining BCG refractory NMIBC. He has lectured all over the country on bladder cancer and have served on special FDA panels, the SITC Immunotherapy Guidelines panel, the Bladder Cancer Task Force and as an external advisor for the MD Anderson Bladder Cancer SPORE.